Skip to content
10-Q

Quarterly Report

FRAZIER LIFESCIENCES ACQUISITION CORPORATION

0001193125-22-147717

← back to feed
Filed
May 12, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$393.68K
Operating Cash Flow restated Q1 2022 · Mar 31, 2021 −$202.46K
Cash And Equivalents Q1 2022 · Mar 31, 2022 $788.04K
Cash And Equivalents Q1 2022 · Dec 31, 2021 $1.23M
Cash And Equivalents Q1 2022 · Mar 31, 2021 $1.16M
Cash And Equivalents Q1 2022 · Dec 31, 2020 $1.37M
Stockholders Equity Q1 2022 · Mar 31, 2022 −$4.97M
Stockholders Equity Q1 2022 · Dec 31, 2021 −$6.36M
Stockholders Equity restated Q1 2022 · Mar 31, 2021 −$7.72M
Stockholders Equity restated Q1 2022 · Dec 31, 2020 −$10.54M
Current Liabilities Q1 2022 · Mar 31, 2022 $107.64K
Current Liabilities Q1 2022 · Dec 31, 2021 $222.07K
Total Liabilities Q1 2022 · Mar 31, 2022 $6.03M
Total Liabilities Q1 2022 · Dec 31, 2021 $7.86M
Current Assets Q1 2022 · Mar 31, 2022 $1.03M
Current Assets Q1 2022 · Dec 31, 2021 $1.49M
Total Assets Q1 2022 · Mar 31, 2022 $139.06M
Total Assets Q1 2022 · Dec 31, 2021 $139.51M
Sga Expense Q1 2022 · Mar 31, 2022 $314.62K
Sga Expense Q1 2022 · Mar 31, 2021 $207.24K
Net Income Q1 2022 · Mar 31, 2022 $1.38M
Net Income Q1 2022 · Mar 31, 2021 $2.82M
Operating Income Q1 2022 · Mar 31, 2022 −$344.62K
Operating Income Q1 2022 · Mar 31, 2021 −$237.24K